Remidio
Remidio is an Indian-founded medtech company that builds portable, AI-assisted eye imaging devices (handheld fundus cameras, slit lamps, autorefractors, corneal scanners) and a cloud teleophthalmology platform for primary care, home care, emergency, rural, and eye care settings globally.
- Company typePrivate
- Founded2011
- HeadquartersGlen Allen, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Remidio does
Remidio is an Indian-founded medical technology company (founded 2011) that develops portable, AI-assisted ophthalmic imaging devices and a cloud-connected teleophthalmology platform. Its product portfolio centers on handheld, battery-powered, non-mydriatic fundus cameras (InstaFOP FOP NM-10, InstaZ), supplemented by a portable digital slit lamp (InstaPSL), a handheld autorefractor (InstaRef R20), a handheld corneal topographer (InstaKC), and an attachment module (AIM) that digitizes existing slit lamps from multiple manufacturers. All devices feed into Remidio Connect, a HIPAA-, ISO 27001-, ISO 27017-, SOC 2 Type 2-, and GDPR-compliant cloud platform with DICOM/EMR/PACS integration, AI-powered clinical decision support (including Medios AI for diabetic retinopathy screening), and optional 24/7 teleophthalmology specialist services.
The company targets non-specialist healthcare settings — primary care providers, home care agencies, rural and mission clinics, emergency departments, and eye care specialists — where traditional ophthalmic equipment is too bulky, expensive, or operator-dependent. Go-to-market is direct enterprise field sales with quote-based, multi-year contracts; the company sells hardware, recurring cloud subscriptions, and managed telehealth services. As of December 2025, the FOP NM-10 received FDA 510(k) clearance, enabling US commercial deployment through Remidio Inc. (Glen Allen, Virginia), while the global headquarters remains in India. Devices are reported to have screened more than 16 million people across 55+ countries, with the company holding granted patents in India, the US, EU, Japan, China, and South Africa and 20+ peer-reviewed publications validating clinical performance.
Remidio firmographics
Firmographics- Name
- Remidio
- Legal name
- Remidio Inc.
- Website
- https://remidio.us
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Remidio is an Indian-founded medtech company that builds portable, AI-assisted eye imaging devices (handheld fundus cameras, slit lamps, autorefractors, corneal scanners) and a cloud teleophthalmology platform for primary care, home care, emergency, rural, and eye care settings globally.
- Ownership category
- akta.pro rank
Remidio industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids) (HLAHAJAN)
- akta.pro secondary industry
- Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)
Keywords
Where Remidio is headquartered
LocationHeadquarters
- HQ city
- Glen Allen
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Remidio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Hardware Sales: Sale of portable eye imaging devices including handheld fundus cameras, corneal scanners, autorefractors, and slit lamps. Devices are sold directly to healthcare organizations with quote-based pricing.
- Cloud Platform and Software Services: Remidio Connect cloud platform for image storage, teleophthalmology consultations, and clinical decision support. May include subscription-based pricing for managed telehealth services with 24/7 eye care providers.
- Enterprise/Telehealth Services: Fully managed teleophthalmology services with real-time access to licensed on-call eye care specialists. Provided as optional 24/7 service for when internal resources are unavailable.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise healthcare pricing - quote-based |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Remidio product offering
Product offeringCore offering
Remidio designs, manufactures, and sells portable, FDA-cleared ophthalmic imaging devices — including handheld fundus cameras, portable slit lamps, autorefractors, and corneal scanners — along with the Remidio Connect cloud-based teleophthalmology platform. Its products enable point-of-care retinal, anterior segment, refractive, and corneal imaging without dilation, with AI-assisted clinical decision support, and are sold to healthcare organizations such as primary care providers, home care agencies, emergency departments, rural/mission programs, and eye care specialists.
Product overview
Remidio offers a portfolio of FDA-cleared portable eye imaging devices designed for point-of-care screening across clinical settings. The product line centers on the InstaFOP and InstaZ fundus cameras for retinal imaging, complemented by the InstaPSL portable slit lamp for anterior segment imaging, InstaRef R20 autorefractor for refraction, and InstaKC corneal scanner for keratoconus detection. The Remidio Connect Cloud Platform serves as the unifying software layer, enabling image storage, AI-powered clinical decision support, and teleophthalmology workflows. The Anterior Imaging Module digitizes existing slit lamps, while the InstaEyeClinic Bag bundles multiple devices for mobile and outreach eye care delivery.
Differentiator
Problem solved
Functional benefit
Brands
- InstaFOP: Handheld Fundus Camera product line for retinal imaging
- InstaPSL
- InstaRef
- InstaZ
- InstaKC
- InstaEyeClinic
- Anterior Imaging Module (AIM)
- Remidio Connect
Quantifiable outcome
- Average length of stay reduced by ~50% when fundus imaging available in ER
- +3 more outcomes
Companies that use Remidio
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles2 records
Remidio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature7 records
Remidio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bill & Melinda Gates FoundationflagshipBill Gates featured Remidio's FDA-cleared Fundus on Phone device in a LinkedIn post, highlighting its ability to detect early signs of conditions like high blood pressure and gestational diabetes, and its potential to reduce stillbirths and improve maternal healthcare globally. This endorsement serves as a significant credibility boost and potential pathway to Gates Foundation partnerships for global health initiatives.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Remidio competitors and assessment
Company assessmentEmerging players
- Eyenuk: Eyenuk develops EyeArt AI for autonomous diabetic retinopathy screening, used with various fundus cameras including handheld devices. It is an emerging peer at the intersection of AI screening software and portable retinal imaging, with overlapping customers and a complementary go-to-market.
- Digital Diagnostics (formerly IDx-DR): Digital Diagnostics develops autonomous AI for diabetic retinopathy screening (LumineticsCore, formerly IDx-DR), the first FDA-authorized autonomous AI diagnostic. It is an emerging peer in the AI-screening software layer that pairs with fundus cameras like Remidio's.
Direct peers
- Topcon Healthcare: Topcon is a leading global manufacturer of ophthalmic imaging devices including fundus cameras and OCT systems. It is a direct peer to Remidio in retinal/retinal-imaging devices for primary care and specialty eye care, though Topcon's portfolio is broader and more established in US hospital channels.
- Nidek: Nidek manufactures ophthalmic diagnostic equipment including fundus cameras, autorefractors, and slit lamps. It is a direct peer across Remidio's product categories (fundus, refraction, anterior imaging) with established global distribution.
- Forus Health: Forus Health is an India-based innovator behind the 3nethra series of handheld fundus cameras used in vision screening programs. It is a direct peer in portable fundus imaging for primary care and rural screening and competes for similar emerging-market screening contracts.
- Carl Zeiss Meditec: Carl Zeiss Meditec manufactures ophthalmic diagnostic devices including fundus cameras, OCT, and perimeters. It is a direct competitor in ophthalmic imaging hardware and digital health, with strong incumbent relationships across US hospital and specialty practices where Remidio is now entering.
- Heidelberg Engineering: Heidelberg Engineering specializes in diagnostic imaging for ophthalmology including Spectralis OCT and confocal fundus imaging systems. It is a direct peer in advanced retinal imaging used by ophthalmologists and hospital eye departments.
- Optomed: Optomed is a Finland-based medical device company specializing in handheld fundus cameras and AI-powered screening software for diabetic retinopathy. It is the closest peer to Remidio in form factor (handheld fundus camera) and target use case (primary-care screening).
- icare (formerly Centervue / Eidon): icare (acquired Centervue) markets the Eidon ultra-widefield confocal fundus imaging system. It is a direct peer in the fundus-imaging category serving both specialty clinics and emerging teleophthalmology workflows.
Broad incumbents
- Canon Eye Care: Canon Eye Care is a broad incumbent in retinal imaging through its CX-1 hybrid and CR-2 digital retinal cameras. It overlaps with Remidio's fundus-imaging offerings but is part of Canon's much larger medical and consumer imaging portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Remidio social profiles
Digital presenceRemidio compliance and trust
Trust signalCompliance6 records
Remidio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Remidio leadership team
Management profileNumber of profiles
Profiles3 records
Remidio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Remidio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Remidio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Remidio
What does Remidio do?
Remidio designs, manufactures, and sells portable, FDA-cleared ophthalmic imaging devices — including handheld fundus cameras, portable slit lamps, autorefractors, and corneal scanners — along with the Remidio Connect cloud-based teleophthalmology platform. Its products enable point-of-care retinal, anterior segment, refractive, and corneal imaging without dilation, with AI-assisted clinical decision support, and are sold to healthcare organizations such as primary care providers, home care agencies, emergency departments, rural/mission programs, and eye care specialists.
Is Remidio a public or private company?
Remidio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Remidio founded?
Remidio was founded in 2011. It employs 1 to 10 people.
Where is Remidio based?
Remidio is headquartered in Glen Allen, United States, in the North America region.
How does Remidio make money?
Three revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are cloud Platform and Software Services and enterprise/Telehealth Services.
Who are Remidio's main competitors?
Emerging players on record are Eyenuk and Digital Diagnostics (formerly IDx-DR). Direct peers are Topcon Healthcare, Nidek, Forus Health, Carl Zeiss Meditec, Heidelberg Engineering, Optomed and icare (formerly Centervue / Eidon). Canon Eye Care is listed as a broad incumbent.
Does Remidio have an API?
No public API is recorded for Remidio.
What industry is Remidio in?
Remidio's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAN, Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids), with a secondary code of HLALAGAL, Ophthalmology & Vision Telemedicine Platforms. Its NAICS code is 339112 and its SIC code is 3841.